Full Press Release Details
New Analysis Shows PrimeC Significantly Improves
Key miRNAs in ALS Patients
Groundbreaking PARADIGM Trial Offers New Hope for ALS Treatment
CAMBRIDGE, Mass., Oct. 24, 2024 /PRNewswire/ -- NeuroSense Therapeutics
Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative
diseases, today announced transformative findings from its PARADIGM clinical trial of PrimeC. These results illuminate a new frontier
in the treatment of ALS (Amyotrophic Lateral Sclerosis), a disease long considered untreatable at its core. The trial demonstrating the
significant impact of PrimeC on the regulation of microRNAs (miRNAs), which play a key role in ALS progression, providing compelling evidence
of the drug's potential to alter the underlying mechanisms of the disease.
ALS is a fatal disease, known for its relentless destruction of motor
neurons, leading to loss of muscle function, speech, and eventually, the ability to breathe. Understanding the molecular drivers of ALS
is key to finding a way to slow or stop its progression. These findings represent a breakthrough in that understanding.
In conclusion, PrimeC demonstrated beneficial regulation of key miRNAs,
supporting its potential to engage critical genetic targets involved in ALS progression. The 2-fold reduction of several miRNAs following
PrimeC treatment is particularly striking, offering both a powerful biomarker for tracking ALS and a potential pathway for new therapeutic
strategies. This regulation of miRNAs underscores PrimeC's capability to influence ALS at the regulatory level, where previous treatments
This work was done in collaboration with Professor Noam Shomron who
is a world-leading scientist in the field of genetics.
The results from the PARADIGM trial reflect NeuroSense Therapeutics'
dedication to developing treatments that go beyond surface-level symptom management, aiming instead to address the root causes of neurodegenerative
diseases. PrimeC's ability to regulate miRNAs represents an important step toward a future where ALS patients have more therapeutic options.
For more information about NeuroSense Therapeutics and its ongoing
research, visit www.neurosense-tx.com.
Amyotrophic lateral sclerosis ("ALS") is an incurable neurodegenerative
disease that causes complete paralysis and death within 2-5 years from diagnosis. Every year, more than 5,000 people are diagnosed with
ALS in the U.S. alone, with an annual disease burden of $1 billion. The number of people living with ALS is expected to grow by 24%
by 2040 in the U.S. and EU.
PARADIGM is a prospective, multinational, randomized, double-blind,
placebo-controlled Phase 2b (NCT05357950) clinical trial of PrimeC in ALS. The trial included 68 participants living with ALS in Canada,
Italy, and Israel. 96% of the trial participants who completed the 6-month double-blind portion of the trial chose to receive treatment
with PrimeC through a 12-month open label extension. Furthermore, to date (June 2024) all participants that completed the 18-month trial
treatment duration, requested to continue PrimeC, which is provided to them in an Investigator Initiated Trial, not limited with time.
As previously reported, in the 6-month double-blind segment of the
trial, the data showed clinically meaningful signs of efficacy with a 29% difference in favor of PrimeC vs placebo in analysis of the
intent to treat (ITT) population. In the PP top-line analysis from PARADIGM, a statistically significant slowing of disease progression
was observed with a 37.4% (p=0.03) difference in ALSFRS-R in favor of PrimeC vs placebo. Most patients enrolled in both the active and
placebo arms of the trial were concurrently treated with Riluzole, the ALS standard of care medication, indicating PrimeC slowed disease
progression well beyond the level afforded by the FDA approved ALS drug.
PrimeC, NeuroSense's lead drug candidate, is a novel extended-release
oral formulation composed of a unique fixed-dose combination of two FDA-approved drugs: ciprofloxacin and celecoxib. PrimeC is designed
to synergistically target several key mechanisms of ALS that contribute to motor neuron degeneration, inflammation, iron accumulation
and impaired ribonucleic acid ("RNA") regulation to potentially inhibit the progression of ALS. NeuroSense completed a Phase
2a clinical trial which met its safety and efficacy endpoints including reducing functional and respiratory deterioration and statistically
significant changes in ALS-related biological markers indicating PrimeC's biological activity. PrimeC was granted Orphan Drug Designation
by the U.S. Food and Drug Administration and the European Medicines Agency.
NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology company
focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes
that these diseases, which include amyotrophic lateral sclerosis (ALS), Alzheimer's disease and Parkinson's disease, among others,
represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients
to date. Due to the complexity of neurodegenerative diseases and based on strong scientific research on a large panel of related biomarkers,
NeuroSense's strategy is to develop combined therapies targeting multiple pathways associated with these diseases.
For additional information, we invite you to visit our website and
and these social media channels.
Forward-Looking Statements
This press release contains "forward-looking statements"
that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press
release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words
such as "anticipate," "believe," "contemplate," "could," "estimate," "expect,"
"intend," "seek," "may," "might," "plan," "potential," "predict,"
"project," "target," "aim," "should," "will" "would," or the negative of these
words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based
on NeuroSense Therapeutics' current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to
predict and include statements regarding Prime C's potential to treat ALS. Further, certain forward-looking statements are based on assumptions
as to future events that may not prove to be accurate. The future events and trends may not occur and actual results could differ materially
and adversely from those anticipated or implied in the forward looking statements. These risks include the risk of a delay in submission
by the Company of its regulatory dossier, that regulatory approvals for PrimeC will be delayed or not obtained in Canada or elsewhere;
that the market opportunity in Canada will not be as currently estimated; unexpected R&D costs or operating expenses, insufficient
capital to complete development of PrimeC, a delay in the reporting of additional results from PARADIGM clinical trial, the timing of
expected regulatory and business milestones, risks associated with meeting with the FDA and Health Canada to determine the best path forward
following the results from PARADIGM clinical trial, including a delay in any such meeting; the potential for PrimeC to safely and effectively
target ALS; preclinical and clinical data for PrimeC; the uncertainty regarding outcomes and the timing of current and future clinical
trials; timing for reporting data; the development and commercial potential of any product candidates of Neurosense; the ability of NeuroSense
to remain listed on Nasdaq; and other risks and uncertainties set forth in NeuroSense's filings with the Securities and Exchange Commission
(SEC). You should not rely on these statements as representing our views in the future. More information about the risks and uncertainties
affecting NeuroSense is contained under the heading "Risk Factors" in the Annual Report on Form 20-F filed with the Securities
and Exchange Commission on April 4, 2024 and NeuroSense's subsequent filings with the SEC. Forward-looking statements contained in this
announcement are made as of this date, and NeuroSense undertakes no duty to update such information except as required under applicable
For further information: Email: info@neurosense-tx.com, Tel: +972